Sofosbuvir/velpatasvir/voxilaprevir
Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.
Combination of | |
---|---|
Sofosbuvir | NS5B RNA polymerase inhibitor |
Velpatasvir | NS5A inhibitor |
Voxilaprevir | NS3/4A protease inhibitor |
Clinical data | |
Trade names | Vosevi |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617037 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
PubChem CID | |
KEGG | |
Chemical and physical data | |
Formula | C111H135F5N17O26PS |
Molar mass | 2281.42 g·mol−1 |
3D model (JSmol) | |
| |
|
Vosevi was approved for medical use in the United States and in the European Union in July 2017.[1][2] Vosevi is sold by Gilead Sciences.
References
- "FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017.
- "Vosevi EPAR". European Medicines Agency (EMA). Retrieved 24 September 2020.
External links
- "Sofosbuvir mixture with velpatasvir and voxilaprevir". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.